Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cx611 for Severe Community-Acquired Bacterial Pneumonia
NCT03158727Phase 2Completed
- Sponsor
- TiGenix
- Start
- Jan 2017
- Primary completion
- Jul 2020
- Modality
- Lipid-based Nanoparticles, Stem Cell Therapies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in community-acquired bacterial pneumonia (CAP) comparing Cx611 with Placebo (2 arms). Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events at 90 days, Number of Participants With Adverse Events of Special Interest at 90 days and 4 more. Started Jan 2017; status: completed.
02
Drugs
Cx611
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT03158727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158727.